Further, Xiao et al. found that intraperitoneal EGCG administration in a rodent model of NASH was able to reduce liver fibrosis through the suppression of oxidative stress and inhibition of NFkB, Akt, and TGF/Suppressor of Mothers against Decapentaplegic (SMAD) signaling [100]. This evidence concerns the gene AKT1 and Hepatic fibrosis.